FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to the preparation of muteins of human lipocalin that specifically bind glypican-3 (hereinafter – GPC3); it can be used in medicine for the treatment of cancer, cells of which express GPC3. Mutant lipocalin is obtained based on mature human neutrophil gelatinase-associated lipocalin (hNGAL). Obtained muteins are also used in a composition of conjugates and fused proteins with a compound that extends the half-life of mutein in blood serum.
EFFECT: invention allows obtaining muteins of lipocalin that specifically bind GPC3 with affinity characterized in a KD value of 0.3 nM or less.
20 cl, 1 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| HUMAN LIPOCALIN 2 MUTEINS (Lcn2, hNGAL) WITH TARGETED AFFINITY | 2019 |
|
RU2804336C2 |
| HUMAN LIPOLOCAL 2 MALLETES (LCN2, HNGAL) WITH AFFINITY FOR SPECIFIC TARGET | 2010 |
|
RU2707126C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
